Literature DB >> 10451007

Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978-1997.

M A Mufson1, R J Stanek.   

Abstract

A surveillance of bacteremic pneumococcal pneumonia was conducted in Huntington, West Virginia, from 1978 to 1997 to investigate case-fatality rates, incidence of disease, capsular types, and antibiotic usage. Our study population comprised consecutive inpatients admitted to the hospitals in Huntington, West Virginia, and included 45 children younger than 15 years and 328 adults. All blood isolates were serotyped by capsular swelling procedures; clinical characteristics, treatment, and outcome for all patients were abstracted from hospital charts. The overall case-fatality rate was 20.3%, with most deaths occurring among adults older than 50 years. Case-fatality rates peaked at 37.7% among patients 80 years of age and older. Only 1 of 45 (2.2%) children died. Case-fatality rates declined in each successive 5-year period, from 30.2% in 1978-1982 to 15.6% in 1993-1997. In that same period, incidence rates increased severalfold among children younger than 4 years to 44.5 cases per 100,000 population and among adults 70 years and 80 years of age and older to 38.5 and 76.2 cases per 100,000, respectively. Of the 34 serotypes isolated, 10 accounted for two thirds of the cases of pneumonia: 1, 4, 9, 14, 3, 6, 12, 5, 23, and 19 (in rank order). Chronic renal disease and arteriosclerotic heart disease increased the risk of death. Treatment regimens that included a macrolide and a penicillin or cephalosporin resulted in the lowest case-fatality rate in adults older than 50 years: 6% in 1993-1997. In conclusion, as bacteremic pneumococcal pneumonia evolved over time, the case-fatality rate decreased, its incidence increased, predominant capsular types changed, and treatment regimens that included a macrolide resulted in the lowest fatality rates.

Entities:  

Mesh:

Year:  1999        PMID: 10451007     DOI: 10.1016/s0002-9343(99)00098-4

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  45 in total

Review 1.  Bacteraemic pneumococcal pneumonia: current therapeutic options.

Authors:  Charles Feldman; Ronald Anderson
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

2.  Gram-Positive Pneumonia.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-06       Impact factor: 3.725

3.  Emergence of a unique penicillin-resistant Streptococcus pneumoniae serogroup 35 strain.

Authors:  Ronald J Stanek; Mary B Maher; Nancy B Norton; Maurice A Mufson
Journal:  J Clin Microbiol       Date:  2010-10-27       Impact factor: 5.948

4.  Optimal antibiotic treatment in severe pneumococcal pneumonia--time for real answers.

Authors:  G W Waterer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-10       Impact factor: 3.267

Review 5.  Optimal therapy for severe pneumococcal community-acquired pneumonia.

Authors:  Manel Luján; Miguel Gallego; Jordi Rello
Journal:  Intensive Care Med       Date:  2006-05-10       Impact factor: 17.440

6.  Addition of a macrolide to a ss-lactam in bacteremic pneumococcal pneumonia.

Authors:  R Dwyer; A Ortqvist; E Aufwerber; B Henriques Normark; T J Marrie; M A Mufson; A Torres; M A Woodhead; M Alenius; M Kalin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-08       Impact factor: 3.267

7.  Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.

Authors:  Lionel A Mandell; Richard G Wunderink; Antonio Anzueto; John G Bartlett; G Douglas Campbell; Nathan C Dean; Scott F Dowell; Thomas M File; Daniel M Musher; Michael S Niederman; Antonio Torres; Cynthia G Whitney
Journal:  Clin Infect Dis       Date:  2007-03-01       Impact factor: 9.079

8.  Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia.

Authors:  Thomas P Lodise; Andrea Kwa; Leon Cosler; Reetu Gupta; Raymond P Smith
Journal:  Antimicrob Agents Chemother       Date:  2007-08-20       Impact factor: 5.191

9.  Are macrolides now obligatory in severe community-acquired pneumonia?

Authors:  Grant W Waterer
Journal:  Intensive Care Med       Date:  2009-12-02       Impact factor: 17.440

Review 10.  Elderly patients with community-acquired pneumonia: optimal treatment strategies.

Authors:  Ulrich Thiem; Hans-Jürgen Heppner; Ludger Pientka
Journal:  Drugs Aging       Date:  2011-07-01       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.